Roflumilast N-oxide prevents cytokine secretion induced by cigarette smoke combined with LPS through JAK/STAT and ERK1/2 inhibition in airway epithelial cells

PLoS One. 2014 Jan 8;9(1):e85243. doi: 10.1371/journal.pone.0085243. eCollection 2014.

Abstract

Cigarette smoke is a major cause of chronic obstructive pulmonary disease (COPD). Airway epithelial cells and macrophages are the first defense cells against cigarette smoke and these cells are an important source of pro-inflammatory cytokines. These cytokines play a role in progressive airflow limitation and chronic airways inflammation. Furthermore, the chronic colonization of airways by Gram-negative bacteria, contributes to the persistent airways inflammation and progression of COPD. The current study addressed the effects of cigarette smoke along with lipolysaccharide (LPS) in airway epithelial cells as a representative in vitro model of COPD exacerbations. Furthermore, we evaluated the effects of PDE4 inhibitor, the roflumilast N-oxide (RNO), in this experimental model. A549 cells were stimulated with cigarette smoke extract (CSE) alone (0.4% to 10%) or in combination with a low concentration of LPS (0.1 µg/ml) for 2 h or 24 h for measurement of chemokine protein and mRNAs and 5-120 min for protein phosphorylation. Cells were also pre-incubated with MAP kinases inhibitors and Prostaglandin E2 alone or combined with RNO, before the addition of CSE+LPS. Production of cytokines was determined by ELISA and protein phosphorylation by western blotting and phospho-kinase array. CSE did not induce production of IL-8/CXCL8 and Gro-α/CXCL1 from A549 cells, but increase production of CCL2/MCP-1. However the combination of LPS 0.1 µg/ml with CSE 2% or 4% induced an important production of these chemokines, that appears to be dependent of ERK1/2 and JAK/STAT pathways but did not require JNK and p38 pathways. Moreover, RNO associated with PGE2 reduced CSE+LPS-induced cytokine release, which can happen by occur through of ERK1/2 and JAK/STAT pathways. We report here an in vitro model that can reflect what happen in airway epithelial cells in COPD exacerbation. We also showed a new pathway where CSE+LPS can induce cytokine release from A549 cells, which is reduced by RNO.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines / pharmacology*
  • Benzamides / pharmacology*
  • Cell Line
  • Chemokine CCL2 / antagonists & inhibitors
  • Chemokine CCL2 / metabolism
  • Chemokine CXCL1 / antagonists & inhibitors
  • Chemokine CXCL1 / metabolism
  • Complex Mixtures / isolation & purification
  • Complex Mixtures / pharmacology*
  • Cyclopropanes / pharmacology
  • Dinoprostone / pharmacology
  • Epithelial Cells / cytology
  • Epithelial Cells / drug effects*
  • Epithelial Cells / metabolism
  • Gene Expression Regulation / drug effects
  • Humans
  • Interleukin-8 / antagonists & inhibitors
  • Interleukin-8 / metabolism
  • Janus Kinases / genetics
  • Janus Kinases / metabolism
  • Lipopolysaccharides / pharmacology*
  • Mitogen-Activated Protein Kinase 1 / genetics
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / genetics
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Nicotiana / chemistry*
  • Phosphodiesterase 4 Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / pharmacology
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Respiratory Mucosa / cytology
  • Respiratory Mucosa / drug effects
  • Respiratory Mucosa / metabolism
  • STAT Transcription Factors / genetics
  • STAT Transcription Factors / metabolism
  • Signal Transduction
  • Smoke / analysis

Substances

  • Aminopyridines
  • Benzamides
  • CCL2 protein, human
  • CXCL1 protein, human
  • Chemokine CCL2
  • Chemokine CXCL1
  • Complex Mixtures
  • Cyclopropanes
  • Interleukin-8
  • Lipopolysaccharides
  • Phosphodiesterase 4 Inhibitors
  • Protein Kinase Inhibitors
  • RNA, Messenger
  • STAT Transcription Factors
  • Smoke
  • Janus Kinases
  • MAPK1 protein, human
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3
  • roflumilast N-oxide
  • Dinoprostone

Grants and funding

This study was supported by INSERM and Falcuté de Pharmacie de Rennes 1. The authors M.L., T.V., V.L., L.C.P., and S.S.V. are grateful to the CAPES–COFECUB for funding and bilateral agreement (Brazil–France). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.